We are live on ! Find out more
ABI

Adamant Biomedical Investments Portfolio holdings

AUM $418M
This Fund
S&P 500
This Quarter Est. Return
+10.95%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$418M
AUM Growth
+$17.7M
Cap. Flow
-$20M
Cap. Flow %
-4.77%
Top 10 Hldgs %
32.81%
Holding
108
New
12
Increased
10
Reduced
35
Closed
7

Top Buys

Rank Stock Value
1
HSP
HOSPIRA INC
HSP
+$5.08M
2
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
+$4.94M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.82M
4
MDVN
MEDIVATION, INC.
MDVN
+$4.68M
5
LGND icon
Ligand Pharmaceuticals
LGND
+$4.24M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$4.8M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$4.11M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.02M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$3.9M
5
QGENF
QIAGEN NV
QGENF
+$3.53M

Sector Composition

Rank Sector Weight
1 Healthcare 87.28%
2 Financials 0.93%
3 Industrials 0.35%
4 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
51
Teva Pharmaceuticals
TEVA
$41.2B
$2.88M 0.69%
50,000
-70,000
-58% -$3.9M
ZBH icon
52
Zimmer Biomet
ZBH
$18.4B
$2.84M 0.68%
25,750
– –
CLVS
53
DELISTED
Clovis Oncology, Inc.
CLVS
$2.8M 0.67%
+50,000
New +$2.63M
ALKS icon
54
Alkermes
ALKS
$8.25B
$2.63M 0.63%
45,000
– –
CERN
55
DELISTED
Cerner Corp
CERN
$2.59M 0.62%
40,000
– –
RDY icon
56
Dr. Reddy's Laboratories
RDY
$10.2B
$2.52M 0.6%
250,000
-150,000
-38% -$1.58M
CBST
57
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$2.42M 0.58%
24,000
– –
QGENF
58
DELISTED
QIAGEN NV
QGENF
$2.34M 0.56%
100,000
-150,610
-60% -$3.53M
SHPG
59
DELISTED
Shire pic
SHPG
$2.34M 0.56%
11,000
– –
MRK icon
60
Merck
MRK
$318B
$2.27M 0.54%
41,920
– –
ALNY icon
61
Alnylam Pharmaceuticals
ALNY
$29.3B
$2.23M 0.53%
23,000
– –
PRXL
62
DELISTED
Parexel International Corp
PRXL
$2.22M 0.53%
+40,000
New +$2.31M
ISRG icon
63
Intuitive Surgical
ISRG
$134B
$2.12M 0.51%
36,000
– –
ARIA
64
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$2.06M 0.49%
300,000
– –
DVA icon
65
DaVita
DVA
$11.7B
$1.97M 0.47%
26,000
– –
BIB icon
66
ProShares Ultra NASDAQ Biotechnology
BIB
$86.2M
$1.88M 0.45%
30,000
-70,000
-70% -$4.11M
PFE icon
67
Pfizer
PFE
$153B
$1.87M 0.45%
63,240
– –
EW icon
68
Edwards Lifesciences
EW
$51.7B
$1.85M 0.44%
87,000
– –
THC icon
69
Tenet Healthcare
THC
$21.1B
$1.77M 0.42%
+35,000
New +$1.83M
VAR
70
DELISTED
Varian Medical Systems, Inc.
VAR
$1.73M 0.41%
22,808
– –
OCR
71
DELISTED
OMNICARE INC
OCR
$1.68M 0.4%
23,000
+5,000
+28% +$339K
BCR
72
DELISTED
CR Bard Inc.
BCR
$1.67M 0.4%
10,000
– –
HNT
73
DELISTED
HEALTH NET INC
HNT
$1.61M 0.38%
+30,000
New +$1.48M
MNKD icon
74
MannKind Corp
MNKD
$1.32B
$1.56M 0.37%
60,000
– –
ATHN
75
DELISTED
Athenahealth, Inc.
ATHN
$1.46M 0.35%
10,000
– –
1 2
3
4 5

Similar funds

AGCJ
Alden Global Capital (Jersey) St. Helier, Jersey $415M AUM 31.95% 1-Year Est. Return
ACM
Alistair Capital Management Dallas, Texas $391M AUM 5.89% 1-Year Est. Return
RNS
Robert N. Shapiro $501M AUM 11.7% 1-Year Est. Return
NTP
Nine Ten Partners Evanston, Illinois $308M AUM
MMC
MDV Management Company Menlo Park, California $296M AUM
LOM
Loeb Offshore Management New York $547M AUM 50.11% 1-Year Est. Return
CAMI
Concord Asset Management (Illinois) Chicago, Illinois $288M AUM 11.06% 1-Year Est. Return
NES
New England Securities New York $285M AUM 7.18% 1-Year Est. Return

Adamant Biomedical Investments's Q4 2014 Portfolio in Review

As of Q4 2014, Adamant Biomedical Investments held 108 positions worth $418M, up 4.4% from $401M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Adamant Biomedical Investments withdrew a net $20M in Q4 2014, closing 7 positions and reducing 35 holdings. Its most notable exit was Insulet, an estimated $2.95M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Financials and Industrials.

Against the trend, Adamant Biomedical Investments opened a new position in HOSPIRA INC worth $5.51M.

  • Adamant Biomedical Investments's largest Q4 2014 buy was HOSPIRA INC: 90,000 shares worth $5.51M.
  • Adamant Biomedical Investments added most to Acadia Pharmaceuticals in Q4 2014, an estimated $4.82M increase.
  • Adamant Biomedical Investments's biggest Q4 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $4.8M.
  • Adamant Biomedical Investments fully exited Insulet in Q4 2014, selling an estimated $2.95M.
  • Adamant Biomedical Investments's ten largest holdings make up 33% of its $418M portfolio in Q4 2014.
  • Adamant Biomedical Investments opened 12 new positions and closed 7 in Q4 2014.
  • Adamant Biomedical Investments's portfolio value rose 4.4% quarter-over-quarter to $418M.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.